H.C. Wainwright analyst Andrew Fein has reiterated their bullish stance on SVRA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors, primarily the significant increase in the estimated aPAP patient population in the U.S. Savara’s updated health claims analysis revealed that the patient population is 50% larger than previously thought, which has led to an increase in the price target from $5 to $8. This larger patient pool alleviates concerns about the market size for Molbreevi, Savara’s anticipated product, and suggests a growing awareness and diagnosis rate of aPAP, which could further expand the market.
Additionally, Savara’s strategic moves, including a non-dilutive debt financing arrangement and ongoing regulatory engagements, contribute to a positive outlook. The company’s active dialogue with the FDA and the tech transfer to Fuji are expected to reduce regulatory risks, enhancing the potential for a successful launch of Molbreevi. These developments, along with the company’s efforts to build a substantial patient pool, support the Buy rating as they indicate a strong potential for growth and market penetration.
Fein covers the Healthcare sector, focusing on stocks such as Biogen, Amylyx Pharmaceuticals Inc, and Insmed. According to TipRanks, Fein has an average return of 15.2% and a 51.12% success rate on recommended stocks.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $16.00 price target.